Cipher Pharmaceuticals Investor Relations Material
Latest events
Q4 2024
Cipher Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cipher Pharmaceuticals Inc
Access all reports
Cipher Pharmaceuticals Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, and commercializing prescription products for the dermatology market in Canada. The company's commercial products include Epuris, a recombinant formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin for treating impetigo; Actikerall, which is indicated for the treatment of hyperkeratotic actinic keratosis; Vaniqa that reduces the growth of unwanted facial hair in women; BRINAVESS, an antiarrhythmic agent for the conversion of recent onset or well-tolerated atrial fibrillation; and AGGRASTAT, an intravenous anti-platelet drug. It also develops PEP005 (ingenol mebutate) gel that completed Phase III clinical trials for actinic keratosis and keloid scars; and CIP-Liprodex (DFF 450), which is in Phase II clinical trials to treat localized liposarcomas.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
CPH
Country
🇨🇦 Canada